SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
SAN DIEGO , Aug. 06, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or “Adamis”) today provided an update on the status of and guidance for the resubmission of the Company’s New Drug Application (“NDA”) for its Epinephrine Pre-filled Syringe (“PFS”) product
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
SAN DIEGO, April 15, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its commercial sales team. These appointments reflect the company's continuing preparations for a sales launch of its epinephrine pre-filled syringe (PFS) for
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
SAN DIEGO, March 27, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") announced that today it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. The study was a Phase I PK study comparing the bioavailability of Adamis'
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") today announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The study was a Phase I open label, randomized, single-dose,
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company") recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No.
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
SAN DIEGO, Jan 09, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
SAN DIEGO, Jan 08, 2015 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology,
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
SAN DIEGO, Dec 02, 2014 (GLOBE NEWSWIRE via COMTEX) -- Adamis Pharmaceuticals Corporation ADMP, -0.64% today announced that the Company is scheduled to present a company overview at two upcoming conferences. Event: 7th Annual LD Micro Conference Date: Wednesday, December 3, 2014
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
SAN DIEGO, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
SAN DIEGO, CA--(Marketwired - Aug 26, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board. Dr. Dennis J.
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
SAN DIEGO, CA--(Marketwired - Aug 19, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
San Diego, California - December 18, 2013 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
San Diego, California - December 18, 2013 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
